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Recent international trends in life expectancy tell a 
remarkable story of improvement.1 In England, life 
expectancy from birth has doubled since 1840 and, from 
1982 to 2012, has increased by about 8 years for men 
(from 71·3 years to 79·2 years) and 6 years for women 
(from 77·3 years to 83.0 years).2 This most recent change 
equates to more than 6 h of life expectancy gained per 
day survived for men, and more than 4 h for women. 
Historically, improvements in life expectancy were 
achieved through reductions in infant and child 
mortality,1 whereas, from 1981 to 2012, life expectancy 
at 65 years improved by 41% for men and 24% for 
women in England; and even at 85 years, by 34% for 
men and 27% for women.2 For men, 39% of deaths in 
the UK now occur at ages older than 85 years, and 52% 
occur at these ages in women, increased from 14% for 
men and 31% for women in 1981.2 In low-mortality 
countries such as England, summary mortality statistics 
therefore mainly track changes in the common 
pathologies of old age.3
Life tables have been used since the 1840s to describe 
geographical inequalities in health. These life tables 
generally correlate strongly with area deprivation,4 
although migration has an eﬀ ect.5 Unfortunately, 
improvement in overall life expectancy has not led to 
commensurate reductions in levels of inequality. The 
range of life expectancy at birth in England across its 
districts increased for males, from 8·3 years in 2008 to 
8·7 years in 2012, although it did fall for women from 
7·3 years to 6·4 years.6 At a regional level, inequalities 
have reduced for men, for whom the range between 
regions fell from 2·7 to 2·4 years, but no change occurred 
for women, for whom the equivalent range remained at 
2·4 years. On a positive note, the gap between men and 
women at a national level has progressively narrowed 
from 5·9 years in 1982 to 3·8 years in 2012.
Statistics on period life expectancy combine age-
speciﬁ c mortality data into a single summary statistic 
that is meaningful to almost any audience. Pitfalls 
exist, however. No one actually experiences period life 
expectancy.6 Just as the satellite navigation system in 
your car tells you how long the journey to an airport 
would take with present traﬃ  c conditions, but not with 
the ones that you will actually encounter, period life 
expectancy is a notional construct based on present 
age-speciﬁ c mortality patterns. In reality, people 
contribute to death statistics as members of birth 
cohorts living through diﬀ erent periods at diﬀ erent 
ages.7 Period life expectancy statistics therefore tell us a 
lot about present mortality experience, but rather little 
about future expectations.
Life expectancy at birth has been projected to 2062 
for England,8 but the uncertainty range is huge. At 
best, the life expectancy of men could be 92·6 years 
and 95·1 years for women, but, at worst, it could be 
81·9 years for men and 85·5 years for women. The main 
estimate is in the middle and represents substantial 
ﬂ attening of present rates of improvement. In 
The Lancet, James Bennett and colleagues9 have used 
elaborate Bayesian models to analyse present mortality 
patterns in England and Wales. They then forecasted life 
expectancy to 2030 for 375 districts. Their models take 
separate account of age, cohort, period, and geography; 
the one that performed best emphasised the eﬀ ect of 
cohort. One of the many beneﬁ ts of this approach is 
that it makes few, if any, assumptions about trends in 
mortality. It allows for non-linear trends of the sort that 
might be expected to follow known patterns of, for 
example, smoking in past decades.
The model output is more optimistic than oﬃ  cial 
ﬁ gures. By 2030, life expectancy is predicted to reach 
85·7 years (95% credible interval 84·2–87·4) for men 
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and 87·6 years (86·7–88·9) for women. The sex gap 
would be reduced to just 1·9 years as mortality is likely 
to continue to improve more for middle-aged and old 
men than it will for women. At district level, the range 
between local areas in 2012 is already equivalent to 
the gap between the UK and countries like Sri Lanka or 
Nicaragua.10 The model predicts increasing inequality 
within England and Wales, with the diﬀ erence between 
the 1st and 99th percentiles rising from 6·1 years 
(5·9–6·4) to 8·3 years (6·8–9·7) for men, and from 
5·6 years (5·3–6·0) to 8·3 years (7·1–9·4) for women.
These results raise important questions about what 
constitutes an adequate response to such worsening 
inequality in terms of both policy and service provision. 
Measures to control smoking remain important, but 
addressing so-called proximal risk factors (such as use 
of tobacco and alcohol, and diet) cannot be expected 
to achieve much unless the social and economic 
determinants of these behaviours change.11 For health 
services, the issue is one of equity not equality—the 
health of the disadvantaged should not be further 
diminished by prevention and treatment services that 
are inadequately adapted to their various situations 
and needs.
Clearly, many predictions of trends in life expectancy 
from the past century were substantially wrong.1 In 
the 1970s, Omran’s12 view of the epidemiological 
transition was that mortality would stabilise once 
infectious diseases had been overcome and mortality 
was dominated by the eﬀ ects of what he called 
“degenerative disease and man-made diseases”, 
such as cardiovascular disease and cancers. Many 
authorities at that time assumed an upper limit for 
life expectancy at birth of 75 years,1 which now seems 
extraordinarily naive. The fact that life expectancy has 
continued its upward trajectory more or less unchecked 
is widely attributed to a profound and abrupt 
decline in mortality from cardiovascular diseases. 
Bongaarts3 ascribed two-thirds of the recent fall in 
deaths in 15 low-mortality countries to a reduction in 
cardiovascular deaths. As a result, cancer is now twice 
as important as a cause of death in these countries as it 
was 50 years ago.
Sustained improvements in life expectancy have 
transformed the age proﬁ le of countries like England, 
with implications for health and care services, 
ﬁ scal policy, the insurance market, and commerce 
generally. Old people of the future will need to be 
healthier and more independent than those using 
services nowadays, otherwise those services could be 
overwhelmed. Aggressive and timely management 
of disability, and a positive approach to promotion of 
health for old people, could still achieve the resilience 
and capability needed. 
Reliable estimates of future life expectancy trends are 
therefore in great demand. Bennett and colleagues9 
have arguably developed to its limit the use of existing 
overall mortality data as a method for prediction of 
future mortality. The next stage is to model trends 
in cause-speciﬁ c mortality for the common causes3,13 
and, even better, to add trends in causes attributable 
to important risk factors. Peto and colleagues14 have 
developed a robust method for estimation of numbers 
of deaths attributable to smoking, which probably 
peaked in England for men in about 1980 and for 
women in 2010. Other attributable risks are technically 
more diﬃ  cult to estimate but these will become 
increasingly important to estimate as the eﬀ ect of 
smoking falls.
In the end, projections are derived from known 
data and remain susceptible to Hume’s problem of 
induction. We implicitly assume that the future will be 
like the past in a predictable way, otherwise even the 
best model is of no value. Unfortunately, experience 
suggests that the future is often rather diﬀ erent 
from the past in really quite unpredictable ways. 
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The UK’s strong contribution to health globally 
The ﬁ rst mapping of the UK’s activities in health globally 
across academia, commerce, government, and the not-
for-proﬁ t sector is provided in The UK’s Contribution to 
Health Globally: Beneﬁ ting the Country and the World,1 
a new report by the All-Party Parliamentary Group on 
Global Health (APPG) published on June 29, 2015. This 
analysis shows that the UK has enormous strengths 
in each of these areas, which could enable the UK to 
make an even greater contribution to improving health 
globally. There are, how ever, risks and threats to this 
position and choices to be made.
The APPG commissioned research from the London 
School of Hygiene & Tropical Medicine to examine 
the UK’s contribution to health globally and assess 
the potential for achieving greater beneﬁ ts. The brief 
was to map UK activities—rather than assess the more 
complex idea of impact—and to consider only activities 
that had improving health as their primary objective. 
The research was undertaken through interviews, 
data collection, and literature review with preliminary 
results discussed with stakeholders; the oﬃ  cers of the 
APPG and the researchers together agreed the report’s 
conclusions and recommendations.
The report reveals strengths in each sector. In 
academia, the UK has three of the top ﬁ ve universities 
in the world for clinical, preclinical, and health sciences; 
two of the top ﬁ ve for life sciences; and the second 
largest share of the top 100 universities for both clinical 
and life sciences.2 The UK ranks ﬁ rst or second among 
G7 countries for research quality by citation impact in 
health-related ﬁ elds.3 The UK has leading funders in 
the Medical Research Council and the Wellcome Trust; 
internationally recognised thinktanks in Chatham 
House and the Overseas Development Institute; and 
world-leading medical and bioscience journals in 
The BMJ, The Lancet, and Nature.
Diﬀ erent parts of government and the public sector 
have major roles in important areas of research, such as 
antimicrobial resistance, dementia, malaria, neglected 
tropical diseases, and, most recently, the response to 
Ebola. The National Health Service (NHS), National 
Institute for Health and Care Excellence, Public Health 
England, the Royal Colleges, and other parts of the 
UK health system are respected for their quality and 
expertise, have many international links, and provide 
volunteers to work in low-income and middle-
income countries. Additionally, the UK Government’s 
Department for International Development makes a 
substantial contribution to health as the second largest 
development agency, with the UK now spending 0·7% 
of gross national income on overseas aid.4
Commercially, the UK Government supports British 
health-care companies to work internationally and 
promote life sciences. There are 4800 companies 
generating more than £55 billion annually, with the 
largest biotech pipeline in Europe.5 Meanwhile, the 
UK has one of the largest and most thriving non-
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